Tectonic Therapeutic Reports 'Minimal' Adverse Events in Phase 1a Trial of TX45 Program
Tectonic Therapeutic (TECX) said late Thursday that its lead asset TX45 for the potential treatment of group 2 pulmonary hypertension in heart failure with preserved ejection fraction showed "minimal" adverse events in a phase 1a clinical trial.
TX45 was well-tolerated and showed a "favorable" pharmacokinetic and pharmacodynamic relationship that was used to identify doses for phase 2 clinical trial, the company said.
"These topline phase 1a findings for TX45 validate the preliminary data previously presented at lower doses, and we look forward to sharing the full trial results at the AHA Scientific Sessions later this year," Tectonic Chief Executive Alise Reicin said.
Price: 19.81, Change: +0.01, Percent Change: +0.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available